Experiment 1218880

Details

PropertyValue
Pharmacology
Administration routeIV
OrganismEmpty organism
CitationANON:. (1990). COMPOUND Q: ARC/AIDS STUDY PROTOCOL: PHASE IB OPEN LABEL, SINGLE IV MULTIPLE DOSE STUDY.. 4(2)
Amount utilized
Compound isolated
DiseaseDISCUSSION OF A CLINICAL TRIAL INVOLVING 12 SUBJECTS STARTING IN NOVEMBER 1989. TREATMENT WILL BE FOR 4 WEEKS AT DOSES OF 8, 16, 24 AND 36 MCG/KG EVERY WEEK FOR 4 WEEKS. EXCLUSION CRITERIA: ANTIVIRALS WITHIN 3 WEEKS PRIOR TO ENTRY, SYSTEMATIC CHEMOTHERAPY LESS THAN 6 WEEKS PRIOR TO ENTRY. STUDY SITES ARE: AIDS COMMUNITY RESEARCH CONSORTIUM(REDWOOD CITY,CA), PORTON MEDICAL GROUP(SHERMAN OAKS,CA), ST.FRANCIS MEMORIAL HOSPITAL(SAN FRANCISCO), U. OF CALIFORNIA MEDICAL CENTER(SAN FRANCISCO) AND VIRX MEDICAL GROUP(SAN FRANCISCO). INCLUSION CRITERIA: PLATELETS MORE THAN 100,000, SGOT/PT LESS THAN 1.5 X NORMAL, BILIRUBIN NORMAL, GRANULOCYTES GREATER THAN 1000, AGE GREATER THAN 18 YEARS, KAMOFSKY SCORE MORE THAN 80.
Dose amount8.0 MCG
Number1
Qualitative result.
AnimalHUMAN ADULT
Per unitKG
Dose expressionDOSE
GenderGIVEN TO BOTH SEXES